The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity
Open accessAbstract
Histone deacetylases (HDACs) compact chromatin structure and repress gene transcription. In schizophrenia, clinical studies demonstrate that HDAC inhibitors are efficacious when given in combination with atypical antipsychotics. However, the molecular mechanism that integrates a better response to antipsychotics with changes in chromatin structure remains unknown. Here we found that chronic atypical antipsychotics downregulated the transcription of metabotropic glutamate 2 receptor (mGlu2, also known as Grm2), an effect that was associated with decreased histone acetylation at its promoter in mouse and human frontal cortex. This epigenetic change occurred in concert with a serotonin 5-HT2A receptor–dependent upregulation and increased binding of HDAC2 to the mGlu2 promoter. Virally mediated overexpression of HDAC2 in frontal cortex decreased mGlu2 transcription and its electrophysiological properties, thereby increasing psychosis-like behavior. Conversely, HDAC inhibitors prevented the repressive histone modifications induced at the mGlu2 promoter by atypical antipsychotics, and augmented their therapeutic-like effects. These observations support the view of HDAC2 as a promising new target for schizophrenia treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Animal models of neuropsychiatric disorders
Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023
Self-citationShaffer, J. P. (1995) · Annual Review of Psychology · doi:10.1146/annurev.ps.46.020195.003021 · Cited by 1,960
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
Self-citationHDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644
Epigenetic regulation in psychiatric disorders
Tsankova, N., Renthal, W., Kumar, A., & Nestler, E. J. (2007) · Nature reviews. Neuroscience · doi:10.1038/nrn2132 · Cited by 1,400
Self-citationEpigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Patil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Self-citationT-maze alternation in the rodent
Deacon, R. M. J., & Rawlins, J. N. P. (2006) · Nature Protocols · doi:10.1038/nprot.2006.2 · Cited by 897
An epigenetic blockade of cognitive functions in the neurodegenerating brain
Gräff, J., Rei, D., Guan, J.-S., Wang, W.-Y., Seo, J., Hennig, K. M., Nieland, T. J. F., Fass, D. M., Kao, P. F., Kahn, M., et al. (2012) · Nature · doi:10.1038/nature10849 · Cited by 853
Identification of a serotonin/glutamate receptor complex implicated in psychosis
González-Maeso, J., Ang, R. L., Yuen, T., Chan, P., Weisstaub, N. V., López-Giménez, J. F., Zhou, M., Okawa, Y., Callado, L. F., Milligan, G., et al. (2008) · Nature · doi:10.1038/nature06612 · Cited by 803
Self-citationSchizophrenia: Diverse Approaches to a Complex Disease
Sawa, A., & Snyder, S. H. (2002) · Science · doi:10.1126/science.1070532 · Cited by 597
Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action
Löscher, W. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00075-6 · Cited by 532
Decoding the Epigenetic Language of Neuronal Plasticity
Borrelli, E., Nestler, E. J., Allis, C. D., & Sassone-Corsi, P. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.012 · Cited by 525
Self-citationEpigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders
ABEL, T., & ZUKIN, R. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.12.002 · Cited by 494
Histone Deacetylase Is a Target of Valproic Acid-Mediated Cellular Differentiation
Gurvich, N., Tsygankova, O. M., Meinkoth, J. L., & Klein, P. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0799 · Cited by 459
Multiple models to capture the variability in biological neurons and networks
Marder, E., & Taylor, A. L. (2011) · Nature Neuroscience · doi:10.1038/nn.2735 · Cited by 451
Tolerance to and physical dependence on morphine in rats
Martin, W. R., Wikler, A., Eades, C. G., & Pescor, F. T. (1963) · Psychopharmacologia · doi:10.1007/bf00408180 · Cited by 446
Serotonin research: contributions to understanding psychoses
GEYER, M., & VOLLENWEIDER, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.006 · Cited by 427
Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia
Egan, M. F., Straub, R. E., Goldberg, T. E., Yakub, I., Callicott, J. H., Hariri, A. R., Mattay, V. S., Bertolino, A., Hyde, T. M., Shannon-Weickert, C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405077101 · Cited by 416
Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected
Agid, O., Kapur, S., Arenovich, T., & Zipursky, R. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.12.1228 · Cited by 408
Cao, J.-L., Covington, H. E., Friedman, A. K., Wilkinson, M. B., Walsh, J. J., Cooper, D. C., Nestler, E. J., & Han, M.-H. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3177-10.2010 · Cited by 402
Self-citationHuman postmortem tissue: What quality markers matter?
Stan, A. D., Ghose, S., Gao, X.-M., Roberts, R. C., Lewis-Amezcua, K., Hatanpaa, K. J., & Tamminga, C. A. (2006) · Brain Research · doi:10.1016/j.brainres.2006.09.025 · Cited by 361
Tamaru, Y., Nomura, S., Mizuno, N., & Shigemoto, R. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00305-0 · Cited by 344
Fribourg, M., Moreno, J. L., Holloway, T., Provasi, D., Baki, L., Mahajan, R., Park, G., Adney, S. K., Hatcher, C., Eltit, J. M., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.055 · Cited by 311
Self-citationGonzález-Maeso, J., Yuen, T., Ebersole, B. J., Wurmbach, E., Lira, A., Zhou, M., Weisstaub, N., Hen, R., Gingrich, J. A., & Sealfon, S. C. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08836.2003 · Cited by 297
Self-citationThe Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia
Goldberg, T. E., Greenberg, R. D., Griffin, S. J., Gold, J. M., Kleinman, J. E., Pickar, D., Schulz, S. C., & Weinberger, D. R. (1993) · British Journal of Psychiatry · doi:10.1192/bjp.162.1.43 · Cited by 289
Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation
Dong, E., Nelson, M., Grayson, D. R., Costa, E., & Guidotti, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805493105 · Cited by 286
NMDA receptors and schizophrenia
KRISTIANSEN, L., HUERTA, I., BENEYTO, M., & MEADORWOODRUFF, J. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.013 · Cited by 246
Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia
Ludewig, K., Geyer, M. A., & Vollenweider, F. X. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01925-x · Cited by 240
Lieberman, J. A., Bymaster, F. P., Meltzer, H. Y., Deutch, A. Y., Duncan, G. E., Marx, C. E., Aprille, J. R., Dwyer, D. S., Li, X.-M., Mahadik, S. P., et al. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00107 · Cited by 220
Fell, M. J., Svensson, K. A., Johnson, B. G., & Schoepp, D. D. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136861 · Cited by 204
Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia and bipolar disorder
Abdolmaleky, H. M., Yaqubi, S., Papageorgis, P., Lambert, A. W., Ozturk, S., Sivaraman, V., & Thiagalingam, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.04.007 · Cited by 192
Chiechio, S., Zammataro, M., Morales, M. E., Busceti, C. L., Drago, F., Gereau, R. W., Copani, A., & Nicoletti, F. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.054346 · Cited by 190
Woolley, M. L., Pemberton, D. J., Bate, S., Corti, C., & Jones, D. N. C. (2008) · Psychopharmacology · doi:10.1007/s00213-007-0974-x · Cited by 189
Dong, E., Guidotti, A., Grayson, D. R., & Costa, E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700529104 · Cited by 188
Psychedelics and schizophrenia
González-Maeso, J., & Sealfon, S. C. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.12.005 · Cited by 166
Self-citationBenneyworth, M. A., Xiang, Z., Smith, R. L., Garcia, E. E., Conn, P. J., & Sanders‐Bush, E. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.035170 · Cited by 161
Moreno, J. L., Kurita, M., Holloway, T. D., López, J., Cadagan, R., Martínez‐Sobrido, L., García‐Sastre, A., & González‐Maeso, J. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.4230-10.2011 · Cited by 125
Self-citationBalancing histone methylation activities in psychiatric disorders
Peter, C. J., & Akbarian, S. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.02.003 · Cited by 111
Citrome, L., Casey, D. E., Daniel, D. G., Wozniak, P., Kochan, L. D., & Tracy, K. A. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.3.290 · Cited by 111
Matrisciano, F., Tueting, P., Maccari, S., Nicoletti, F., & Guidotti, A. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.274 · Cited by 110
The cortical serotonin2Areceptor and the pathology of schizophrenia: a likely accomplice
Dean, B. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01693.x · Cited by 100
Chromatin immunoprecipitation in postmortem brain
Huang, H., Matevossian, A., Jiang, Y. P., & Akbarian, S. (2006) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2006.02.018 · Cited by 96
González‐Maeso, J., Rodríguez‐Puertas, R., Meana, J. J., Garcı́a-Sevilla, J. A., & Guimón, J. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001067 · Cited by 94
Self-citationAdjunct Divalproex or Lithium to Clozapine in Treatment-Resistant Schizophrenia
Kelly, D. L., Conley, R. R., Feldman, S. M., Yu, Y., McMahon, R. P., & Richardson, C. M. (2006) · Psychiatric Quarterly · doi:10.1007/s11126-006-7963-9 · Cited by 78
Zhai, Y. W., George, C., Zhai, J., Nisenbaum, E. S., Johnson, M. P., & Nisenbaum, L. K. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300013 · Cited by 73
Regional and subcellular distribution of HDAC4 in mouse brain
Darcy, M. J., Calvin, K., Cavnar, K., & Ouimet, C. C. (2010) · Journal of Comparative Neurology · doi:10.1002/cne.22241 · Cited by 69
Group II metabotropic glutamate receptors and schizophrenia
Moreno, J. L., Sealfon, S. C., & González‐Maeso, J. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0130-3 · Cited by 62
Self-citationSuzuki, T., Uchida, H., Takeuchi, H., Nakajima, S., Nomura, K., Tanabe, A., Yagi, G., Watanabe, K., & Kashima, H. (2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1073 · Cited by 57
Humphrey, G. W., Wang, Y., Hirai, T. H., Padmanabhan, R., Panchision, D. M., Newell, L. F., McKay, R. D. G., & Howard, B. H. (2007) · Differentiation · doi:10.1111/j.1432-0436.2007.00232.x · Cited by 54
Liu, W., Downing, A. C., Munsie, L. M., Chen, P., Reed, M. R., Ruble, C., Landschulz, K. T., Kinon, B. J., & Nisenbaum, L. K. (2010) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.90 · Cited by 52
Aghajanian, G. K. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1484-9 · Cited by 44
Schizophrenia: The making of a troubled mind
Dobbs, D. E. (2010) · Nature · doi:10.1038/468154a · Cited by 40
Pharmacotherapy for treatment-refractory schizophrenia
Sant, S. V., & Buckley, P. F. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.528200 · Cited by 28
Cited by
Histone acetylation: molecular mnemonics on the chromatin
Gräff, J., & Tsai, L.-H. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3427 · Cited by 680
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
Epigenetic basis of mental illness
Nestler, E. J., Peña, C. J., Kundakovic, M., Mitchell, A., & Akbarian, S. (2016) · The Neuroscientist · doi:10.1177/1073858415608147 · Cited by 342
Self-citationNasca, C., Xenos, D., Barone, Y., Caruso, A., Scaccianoce, S., Matrisciano, F., Battaglia, G., Mathé, A. A., Pittaluga, A., Lionetto, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216100110 · Cited by 263
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Metadata
- Authors
- Kurita, M., Holloway, T., García-Bea, A., Kozlenkov, A., Friedman, A. K., Moreno, J. L., Heshmati, M., Golden, S. A., Kennedy, P. J., Takahashi, N., Dietz, D. M., Mocci, G., Gabilondo, A. M., Hanks, J., Umali, A., Callado, L. F., Gallitano, A. L., Neve, R. L., Shen, L., Buxbaum, J. D., Han, M.-H., Nestler, E. J., Meana, J. J., Russo, S. J., & González-Maeso, J.
- Venue
- Nature Neuroscience
- Published
- 2012-08-05
- Volume
- 15
- Issue
- 9
- Pages
- 1245-1254
- ISSN
- 1097-6256 (ISSN-L)
- 1546-1726
- OpenAlex
- W2134946659
- Cited by
- 285
- References
- 59
- FWCI
- 20.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.